WO2004009618A2
(en)
|
2002-07-18 |
2004-01-29 |
Crucell Holland B.V. |
Recombinant production of mixtures of antibodies
|
US6908744B1
(en)
*
|
2000-03-14 |
2005-06-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of stimulating cartilage formation
|
AU8337701A
(en)
*
|
2000-08-14 |
2002-02-25 |
Us Health |
Enhanced homologous recombination mediated by lambda recombination proteins
|
US6586251B2
(en)
*
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
AU2003304106C1
(en)
|
2002-05-17 |
2010-10-28 |
Mount Sinai School Of Medicine Of New York University |
Mesoderm and definitive endoderm cell populations
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
EP1539946A4
(en)
*
|
2002-09-09 |
2006-03-15 |
California Inst Of Techn |
METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE
|
WO2004067725A2
(en)
*
|
2003-01-30 |
2004-08-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of identifying modulators of nmur2-mediated activity
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
EP1639009B1
(en)
|
2003-05-30 |
2013-02-27 |
Merus B.V. |
Fab library for the preparation of a mixture of antibodies
|
DK2767161T3
(en)
|
2004-10-19 |
2018-05-07 |
Regeneron Pharma |
Method of generating an animal homozygous for genetic modification
|
US20060117396A1
(en)
*
|
2004-11-30 |
2006-06-01 |
Murphy Andrew J |
Assay methods for identifying modulators of OPSDL3 and transgenic knockouts
|
EP2125894B1
(en)
|
2007-03-22 |
2018-12-19 |
Biogen MA Inc. |
Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
|
NZ581396A
(en)
|
2007-06-01 |
2012-07-27 |
Omt Inc |
Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
|
KR20100103810A
(ko)
*
|
2007-12-10 |
2010-09-28 |
알리바 바이오파마수티컬스, 아이엔씨. |
동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법
|
CA2720903C
(en)
*
|
2008-04-14 |
2019-01-15 |
Sangamo Biosciences, Inc. |
Linear donor constructs for targeted integration
|
US20090328240A1
(en)
*
|
2008-06-24 |
2009-12-31 |
Sing George L |
Genetically modified mice as predictors of immune response
|
DE102008002715A1
(de)
*
|
2008-06-27 |
2009-12-31 |
Evonik Röhm Gmbh |
2-Hydroxyisobuttersäure produzierende rekombinante Zelle
|
EP3889265A1
(en)
|
2008-09-30 |
2021-10-06 |
Ablexis, LLC |
Transgenic mice for the production of chimeric antibodies
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
NO2792236T3
(ja)
|
2009-07-08 |
2018-04-14 |
|
|
EP2485583B1
(en)
|
2009-10-06 |
2016-07-06 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice and engraftment
|
CA2779858C
(en)
*
|
2009-10-29 |
2019-10-29 |
Aris N. Economides |
Multifunctional alleles
|
LT2954779T
(lt)
|
2009-12-10 |
2019-05-27 |
Regeneron Pharmaceuticals, Inc. |
Pelės, gaminančios sunkiosios grandinės antikūnus
|
RU2549695C2
(ru)
|
2009-12-21 |
2015-04-27 |
Ридженерон Фармасьютикалз, Инк. |
ГУМАНИЗИРОВАННЫЕ FCγR МЫШИ
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
WO2011097603A1
(en)
|
2010-02-08 |
2011-08-11 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
KR101830020B1
(ko)
|
2010-03-31 |
2018-02-19 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
CA2804311C
(en)
|
2010-06-22 |
2017-09-12 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a light chain with human lambda variable and mouse constant regions
|
JP6482757B2
(ja)
|
2010-07-26 |
2019-03-13 |
トリアンニ インコーポレイテッドTrianni,Inc. |
トランスジェニック動物および使用方法
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
EP2947151A1
(en)
|
2010-08-02 |
2015-11-25 |
Regeneron Pharmaceuticals, Inc. |
Binding proteins comprising vl domains
|
WO2012063048A1
(en)
|
2010-11-08 |
2012-05-18 |
Kymab Limited |
Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
|
ES2865068T3
(es)
|
2011-01-14 |
2021-10-14 |
Univ California |
Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos
|
SG10202008003VA
(en)
|
2011-02-15 |
2020-10-29 |
Regeneron Pharma |
Humanized m-csf mice
|
US10920242B2
(en)
|
2011-02-25 |
2021-02-16 |
Recombinetics, Inc. |
Non-meiotic allele introgression
|
DE12716101T1
(de)
|
2011-02-25 |
2013-05-08 |
Regeneron Pharmaceuticals, Inc. |
Adam6-mäuse
|
DK2631654T3
(en)
|
2011-05-12 |
2015-07-20 |
Regeneron Pharma |
Neuropeptidfrigivelsesassay to sodium
|
SG10201606158TA
(en)
|
2011-08-05 |
2016-09-29 |
Regeneron Pharma |
Humanized universal light chain mice
|
CN107056936B
(zh)
|
2011-09-19 |
2021-09-03 |
科马布有限公司 |
免疫球蛋白基因多样性的操纵及多抗体治疗剂
|
JP2014531452A
(ja)
|
2011-09-19 |
2014-11-27 |
カイマブ・リミテッド |
動物、レパートリーおよび方法
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
CA2850534A1
(en)
|
2011-10-17 |
2013-04-25 |
Regeneron Pharmaceuticals, Inc. |
Restricted immunoglobulin heavy chain mice
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
IN2014CN03892A
(ja)
|
2011-10-28 |
2015-10-16 |
Regeneron Pharma |
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
HUE045879T2
(hu)
|
2011-10-28 |
2020-01-28 |
Regeneron Pharma |
Genetikailag módosított fõ hisztokompatibilitási komplexes egerek
|
ES2858978T3
(es)
|
2011-10-28 |
2021-09-30 |
Regeneron Pharma |
Ratones con receptores de linfocitos T genéticamente modificados
|
JP2014532655A
(ja)
|
2011-10-31 |
2014-12-08 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
ナノ懸濁過程
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
HUE044266T2
(hu)
|
2011-12-20 |
2019-10-28 |
Regeneron Pharma |
Humanizált könnyûláncú egerek
|
RU2770016C2
(ru)
|
2012-02-01 |
2022-04-14 |
Регенерон Фармасьютикалз, Инк. |
Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl
|
KR20140136462A
(ko)
|
2012-03-06 |
2014-11-28 |
리제너론 파마슈티칼스 인코포레이티드 |
공통 경쇄 마우스
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
SI2825037T1
(sl)
|
2012-03-16 |
2019-08-30 |
Regeneron Pharmaceuticals, Inc. |
Glodavci, ki izražajo PH občutljiva zaporedja imunoglobulina
|
PT2825036T
(pt)
|
2012-03-16 |
2018-07-26 |
Regeneron Pharma |
Anticorpos de cadeia leve manipulados em histidina e roedores geneticamente modificados para gerar os mesmos
|
RU2014141536A
(ru)
|
2012-03-16 |
2016-05-10 |
Регенерон Фармасьютикалз, Инк. |
Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
WO2013144567A1
(en)
|
2012-03-28 |
2013-10-03 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
|
SG11201406547YA
(en)
|
2012-04-25 |
2014-11-27 |
Regeneron Pharma |
Nuclease-mediated targeting with large targeting vectors
|
KR102266274B1
(ko)
|
2012-06-12 |
2021-06-17 |
리제너론 파마슈티칼스 인코포레이티드 |
제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
|
AR091482A1
(es)
*
|
2012-06-21 |
2015-02-04 |
Recombinetics Inc |
Celulas modificadas geneticamente y metodos par su obtencion
|
BR112015003751B1
(pt)
|
2012-08-23 |
2021-12-07 |
Agensys, Inc. |
Conjugados anticorpo-fármaco, uso dos mesmos, composição farmacêutica, vetor, anticorpos ou fragmentos de ligação ao antígeno, método para produzir os mesmos e anticorpo ou fragmento de ligação ao antígeno que se liga a 158p1d7
|
WO2014031174A1
(en)
|
2012-08-24 |
2014-02-27 |
The Regents Of The University Of California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
CN108782459B
(zh)
|
2012-09-07 |
2021-11-05 |
再生元制药公司 |
经遗传修饰的非人动物及其使用方法
|
UA118090C2
(uk)
*
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
JP6422441B2
(ja)
|
2012-11-05 |
2018-11-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
遺伝学的に修飾された非ヒト動物およびその使用法
|
JP6475172B2
(ja)
|
2013-02-20 |
2019-02-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
ラットの遺伝子組換え
|
EP3351095A1
(en)
|
2013-02-20 |
2018-07-25 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with modified immunoglobulin heavy chain sequences
|
PL2958938T3
(pl)
|
2013-02-20 |
2019-11-29 |
Regeneron Pharma |
Myszy eksprymujące humanizowane ko-receptory komórek t
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
CN105164154B
(zh)
|
2013-02-22 |
2019-06-07 |
瑞泽恩制药公司 |
表达人源化主要组织相容性复合物的小鼠
|
ES2764829T3
(es)
|
2013-03-11 |
2020-06-04 |
Regeneron Pharma |
Ratones transgénicos que expresan moléculas quiméricas del complejo mayor de histocompatibilidad (mhc) de clase I
|
KR102309653B1
(ko)
|
2013-03-11 |
2021-10-08 |
리제너론 파아마슈티컬스, 인크. |
키메라 주요 조직적합성 복합체 (mhc) 제ii부류 분자를 발현하는 유전자전이 마우스
|
LT3501272T
(lt)
|
2013-03-13 |
2023-03-27 |
Regeneron Pharmaceuticals, Inc. |
Pelės, vykdančios imunoglobulino lengvosios grandinės riboto rinkinio raišką
|
SG11201506294TA
(en)
|
2013-03-13 |
2015-09-29 |
Regeneron Pharma |
Common light chain mouse
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
US20140310828A1
(en)
|
2013-04-16 |
2014-10-16 |
Regeneron Pharmaceuticals, Inc. |
Targeted modification of rat genome
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
CN105722534B
(zh)
|
2013-08-01 |
2019-05-31 |
艾更斯司股份有限公司 |
结合cd37蛋白的抗体药物偶联物(adc)
|
MY182065A
(en)
|
2013-08-07 |
2021-01-18 |
Regeneron Pharma |
Lincrna-deficient non-human animals
|
KR20200103882A
(ko)
|
2013-09-18 |
2020-09-02 |
리제너론 파마슈티칼스 인코포레이티드 |
히스티딘 엔지니어링된 경쇄 항체 및 그것을 생성하기 위한 유전자 변형된 비-인간 동물
|
PT2922394T
(pt)
|
2013-09-23 |
2017-05-22 |
Regeneron Pharma |
Animais não-humanos tendo um gene humanizado da proteína reguladora de sinal
|
WO2015049517A2
(en)
|
2013-10-01 |
2015-04-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
CA2929774C
(en)
|
2013-11-19 |
2020-09-15 |
Regeneron Pharmaceuticals, Inc. |
Non-human animal cells having a humanized proliferation-inducing ligand gene
|
EP3071024B1
(en)
|
2013-11-19 |
2018-09-05 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized b-cell activating factor gene
|
SI3080279T1
(sl)
|
2013-12-11 |
2019-01-31 |
Regeneron Pharmaceuticals, Inc. |
Postopki in sestavki za ciljano spremembo genoma
|
CA2933433C
(en)
*
|
2013-12-11 |
2020-11-17 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
US11160879B2
(en)
|
2014-01-15 |
2021-11-02 |
Masamichi Yamamoto |
Transgenic animal for visualization of ATP and use thereof
|
CA2942697A1
(en)
|
2014-03-21 |
2015-09-24 |
Lynn Macdonald |
Non-human animals that make single domain binding proteins
|
RU2016141123A
(ru)
|
2014-03-21 |
2018-04-23 |
Регенерон Фармасьютикалз, Инк. |
Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
|
WO2015179317A2
(en)
|
2014-05-19 |
2015-11-26 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified non-human animals expressing human epo
|
AU2015266841C1
(en)
|
2014-05-30 |
2018-06-07 |
Regeneron Pharmaceuticals, Inc. |
Humanized dipeptidyl peptidase IV (DPP4) animals
|
JP6688231B2
(ja)
|
2014-06-06 |
2020-04-28 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
標的遺伝子座を修飾するための方法及び組成物
|
SI3157956T1
(sl)
|
2014-06-19 |
2020-06-30 |
Regeneron Pharmaceuticals, Inc. |
Nehumane živali, ki imajo humaniziran gen programirane celične smrti 1
|
PL3354732T3
(pl)
|
2014-06-23 |
2020-06-15 |
Regeneron Pharmaceuticals, Inc. |
Łączenie dna mediowane nukleazą
|
RS58009B1
(sr)
|
2014-06-26 |
2019-02-28 |
Regeneron Pharma |
Postupci i supstance za ciljane genetske modifikacije i načini upotrebe
|
JP2017529841A
(ja)
|
2014-09-19 |
2017-10-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
キメラ抗原受容体
|
EP3561052A1
(en)
|
2014-10-15 |
2019-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for generating or maintaining pluripotent cells
|
CA2968440A1
(en)
*
|
2014-11-21 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modification using paired guide rnas
|
CA2967823A1
(en)
|
2014-11-24 |
2016-06-02 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing humanized cd3 complex
|
RU2728412C2
(ru)
|
2014-12-05 |
2020-07-29 |
Регенерон Фармасьютикалз, Инк. |
Животные, отличные от человека, имеющие гуманизированный ген кластера дифференцировки 47
|
DK3808775T3
(da)
|
2014-12-09 |
2024-07-01 |
Regeneron Pharma |
Ikke-humaniserede dyr med en klynge af differenteringsgenet 274
|
JP6840077B2
(ja)
|
2014-12-19 |
2021-03-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物
|
WO2016145099A1
(en)
|
2015-03-09 |
2016-09-15 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
ES2830173T3
(es)
|
2015-03-16 |
2021-06-03 |
Regeneron Pharma |
Animal no humano que presenta función de las neuronas motoras superiores e inferiores y percepción sensorial disminuidas
|
EP3271403A1
(en)
|
2015-03-19 |
2018-01-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
FI3280257T3
(fi)
|
2015-04-06 |
2023-09-07 |
Regeneron Pharma |
Humanisoituja t-soluvälitteisiä immuunivasteita ei-ihmiseläimillä
|
MX2017013285A
(es)
|
2015-04-13 |
2018-08-01 |
Regeneron Pharma |
Ratones con genes insertados de sirpa-il15 humanizadas y métodos para usarlos.
|
US10395759B2
(en)
|
2015-05-18 |
2019-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for copy number variant detection
|
ES2784360T3
(es)
*
|
2015-05-29 |
2020-09-24 |
Regeneron Pharma |
Animales no humanos que tienen una interrupción en un locus C9ORF72
|
CN108135151A
(zh)
|
2015-09-02 |
2018-06-08 |
瑞泽恩制药公司 |
***癌的啮齿动物模型
|
WO2017087780A1
(en)
*
|
2015-11-20 |
2017-05-26 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized lymphocyte-activation gene 3
|
DE102016122317A1
(de)
*
|
2015-11-24 |
2017-05-24 |
Glaxosmithkline Intellectual Property Development Limited |
Transientes transfektionsverfahren für retrovirale produktion
|
WO2017089308A1
(en)
*
|
2015-11-24 |
2017-06-01 |
Glaxosmithkline Intellectual Property Development Limited |
Stable cell lines for retroviral production
|
EP3384030A4
(en)
|
2015-12-03 |
2019-07-03 |
Trianni, Inc. |
IMPROVED IMMUNOGLULINIVITY
|
IL260526B2
(en)
|
2016-01-13 |
2023-10-01 |
Regeneron Pharma |
Rodents with an engineered heavy chain diversity region
|
US20170218398A1
(en)
*
|
2016-01-30 |
2017-08-03 |
Markus Alexander Brown |
Method to selectively target cancerous cells for genetic manipulation
|
SG11201806176PA
(en)
*
|
2016-02-04 |
2018-08-30 |
Regeneron Pharma |
Non-human animals having an engineered angptl8 gene
|
CA3012833A1
(en)
|
2016-02-04 |
2017-08-10 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
EP3416479A1
(en)
|
2016-02-16 |
2018-12-26 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a mutant kynureninase gene
|
AU2017228293B2
(en)
|
2016-02-29 |
2023-05-25 |
Regeneron Pharmaceuticals, Inc. |
Rodents having a humanized Tmprss gene
|
KR20180132727A
(ko)
|
2016-03-29 |
2018-12-12 |
리제너론 파마슈티칼스 인코포레이티드 |
유전자 변이체 표현형 분석 시스템 및 사용 방법
|
KR102628909B1
(ko)
|
2016-05-20 |
2024-01-25 |
리제너론 파마슈티칼스 인코포레이티드 |
다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법
|
CN116458475A
(zh)
|
2016-06-03 |
2023-07-21 |
瑞泽恩制药公司 |
表达外源末端脱氧核苷酸转移酶的非人动物
|
KR20190022752A
(ko)
|
2016-06-27 |
2019-03-06 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조합
|
US10912287B2
(en)
|
2016-06-28 |
2021-02-09 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd |
Genetically modified mice expressing humanized PD-1
|
RU2721125C1
(ru)
|
2016-07-29 |
2020-05-18 |
Регенерон Фармасьютикалз, Инк. |
Мыши, содержащие мутации, вследствие которых экспрессируется укороченный на с-конце фибриллин-1
|
KR102294755B1
(ko)
|
2016-09-30 |
2021-08-31 |
리제너론 파마슈티칼스 인코포레이티드 |
C9orf72 유전자좌에서 헥사뉴클레오티드 반복 확장을 갖는 비인간 동물
|
CN114369157A
(zh)
|
2016-11-04 |
2022-04-19 |
瑞泽恩制药公司 |
具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
|
SG10202109874VA
(en)
|
2017-01-19 |
2021-10-28 |
Open Monoclonal Tech Inc |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
SG11201907490XA
(en)
|
2017-02-27 |
2019-09-27 |
Regeneron Pharma |
Non-human animal models of retinoschisis
|
CA3068072A1
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for assessing crispr/cas-mediated disruption or excision and crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
|
CN115074343A
(zh)
|
2017-07-31 |
2022-09-20 |
瑞泽恩制药公司 |
Cas转基因小鼠胚胎干细胞和小鼠及其应用
|
MX2020003589A
(es)
|
2017-09-29 |
2020-07-22 |
Regeneron Pharma |
Animales no humanos que comprenden un locus ttr humanizado y metodos de uso.
|
DK3687287T3
(da)
|
2017-09-29 |
2023-10-16 |
Regeneron Pharma |
Gnavere, udtrykkende humaniseret c1q-kompleks
|
WO2019072241A1
(en)
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
|
CN109666701B
(zh)
*
|
2017-10-13 |
2021-08-24 |
百奥赛图(北京)医药科技股份有限公司 |
一种pd-1基因修饰人源化动物模型的构建方法及其应用
|
US11419318B2
(en)
|
2017-11-30 |
2022-08-23 |
Regeneran Pharmaceuticals, Inc. |
Genetically modified rat comprising a humanized TRKB locus
|
RS63772B1
(sr)
|
2017-12-05 |
2022-12-30 |
Regeneron Pharma |
Miševi koji imaju modifikovani lambda laki lanac imunoglobulina i njihove upotrebe
|
JP7334178B2
(ja)
|
2018-03-19 |
2023-08-28 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
CRISPR/Cas系を使用した動物での転写モジュレーション
|
SG11202008620VA
(en)
|
2018-03-26 |
2020-10-29 |
Regeneron Pharma |
Humanized rodents for testing therapeutic agents
|
WO2019232307A1
(en)
|
2018-06-01 |
2019-12-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for sparse vector-based matrix transformations
|
HRP20220509T8
(hr)
|
2018-06-14 |
2022-07-22 |
Regeneron Pharmaceuticals, Inc. |
Ne-humane životinje sposobne za dh-dh preraspodjelu kodirajućim sekvencama teškog lanca imunoglobulina
|
EP3823443B1
(en)
|
2018-07-16 |
2024-05-22 |
Regeneron Pharmaceuticals, Inc. |
Rodent models of ditra disease and uses thereof
|
CN109504708A
(zh)
*
|
2018-12-03 |
2019-03-22 |
江苏集萃药康生物科技有限公司 |
一种筛选标记自我删除的基因打靶载体及方法
|
MX2021007400A
(es)
|
2018-12-20 |
2021-07-15 |
Regeneron Pharma |
Expansion de repeticiones mediada por nucleasas.
|
WO2020152607A1
(en)
|
2019-01-22 |
2020-07-30 |
St. Jude Children's Research Hospital |
Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
|
AU2020226445A1
(en)
|
2019-02-18 |
2021-07-08 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Genetically modified non-human animals with humanized immunoglobulin locus
|
MX2021009855A
(es)
|
2019-02-22 |
2021-09-10 |
Regeneron Pharma |
Roedores que tienen canales de sodio modificados geneticamente y metodos de uso de los mismos.
|
IL286917B
(en)
|
2019-04-04 |
2022-09-01 |
Regeneron Pharma |
Methods for scar-free insertion of targeted modifications into targeted vectors
|
EP3772929B1
(en)
*
|
2019-04-04 |
2023-11-15 |
Regeneron Pharmaceuticals, Inc. |
Rodents comprising a humanized coagulation factor 12 locus
|
JP2022529943A
(ja)
|
2019-04-15 |
2022-06-27 |
クウィクセル セラピューティクス リミテッド ライアビリティ カンパニー |
がんの処置における使用のための、標的指向性のマスクされたi型インターフェロン(ifnaおよびifnb)と腫瘍抗原に対する抗体とを含む融合タンパク質組成物
|
CN113874510A
(zh)
|
2019-06-04 |
2021-12-31 |
瑞泽恩制药公司 |
包括具有β滑移突变的人源化TTR基因座的非人动物和使用方法
|
JP2022535418A
(ja)
|
2019-06-05 |
2022-08-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
カッパ遺伝子座から発現される限られたラムダ軽鎖レパートリーを有する非ヒト動物及びその使用
|
CN113939595A
(zh)
|
2019-06-07 |
2022-01-14 |
瑞泽恩制药公司 |
包括人源化白蛋白基因座的非人动物
|
EP3990475A1
(en)
|
2019-06-27 |
2022-05-04 |
Regeneron Pharmaceuticals, Inc. |
Modeling tdp-43 proteinopathy
|
JP2022538674A
(ja)
|
2019-07-01 |
2022-09-05 |
トニックス ファーマ リミテッド |
抗cd154抗体およびその使用
|
US20240058466A1
(en)
|
2019-10-04 |
2024-02-22 |
TAE Life Sciences |
Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
CN115175559A
(zh)
|
2020-01-28 |
2022-10-11 |
瑞泽恩制药公司 |
包含人源化pnpla3基因座的非人动物及其使用方法
|
WO2021158883A1
(en)
|
2020-02-07 |
2021-08-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized klkb1 locus and methods of use
|
US20230102342A1
(en)
|
2020-03-23 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
EP4138550A1
(en)
|
2020-04-21 |
2023-03-01 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized cxcl13 gene
|
CN115667532A
(zh)
|
2020-06-02 |
2023-01-31 |
百奥赛图(北京)医药科技股份有限公司 |
具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物
|
RU2751237C1
(ru)
*
|
2020-06-10 |
2021-07-12 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
EP4173480A4
(en)
|
2020-06-25 |
2024-04-17 |
Humab Co. Ltd. |
HETEROZYGOUS TRANSGENIC ANIMAL
|
US20220090060A1
(en)
|
2020-09-11 |
2022-03-24 |
Regeneron Pharmaceuticals, Inc. |
Identification and production of antigen-specific antibodies
|
EP4221496A1
(en)
|
2020-10-01 |
2023-08-09 |
Regeneron Pharmaceuticals, Inc. |
Rodent animals expressing human cr1
|
US12012441B2
(en)
|
2020-10-26 |
2024-06-18 |
Neptune Biosciences Llc |
Engineered human IL-21 cytokines and methods for using the same
|
IL303626A
(en)
|
2020-12-16 |
2023-08-01 |
Regeneron Pharma |
Mice expressing human FC alpha receptors
|
CN116802200A
(zh)
|
2020-12-21 |
2023-09-22 |
瑞泽恩制药公司 |
具有人源化tslp基因、人源化tslp受体基因和/或人源化il7ra基因的非人动物
|
EP4051700A1
(en)
|
2020-12-23 |
2022-09-07 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses thereof
|
MX2023008055A
(es)
|
2021-01-06 |
2023-08-22 |
Tonix Pharma Ltd |
Métodos para inducir tolerancia inmune con anticuerpos anti-cd154 modificados.
|
WO2022212582A1
(en)
|
2021-03-31 |
2022-10-06 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
|
EP4324848A1
(en)
|
2021-04-16 |
2024-02-21 |
Korea University Research and Business Foundation |
Human antibody targeting covid-19 virus
|
KR20240021943A
(ko)
|
2021-06-18 |
2024-02-19 |
남미 테라퓨틱스, 인크. |
암의 치료에 사용하기 위한 마스킹된 유형 I 인터페론 (IFNα 및 IFNβ)을 포함하는 융합 단백질 조성물(들) 및 그의 방법
|
WO2023077053A2
(en)
|
2021-10-28 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
CA3238939A1
(en)
|
2021-12-08 |
2023-06-15 |
Gaurang Patel |
Mutant myocilin disease model and uses thereof
|
WO2023122506A1
(en)
|
2021-12-20 |
2023-06-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising humanized ace2 and tmprss loci
|
WO2023150798A1
(en)
|
2022-02-07 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
AU2023218391A1
(en)
|
2022-02-11 |
2024-07-11 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for screening 4r tau targeting agents
|
WO2023212560A1
(en)
|
2022-04-26 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
A rodent model of fibrodysplasia ossificans progressiva
|
WO2023235677A1
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Animal model of tdp-43 proteinopathy
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
US20230417899A1
(en)
|
2022-06-27 |
2023-12-28 |
Oshkosh Corporation |
Position tracking for a lift device
|
US20240102045A1
(en)
|
2022-07-19 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
WO2024064860A1
(en)
|
2022-09-22 |
2024-03-28 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice expressing components of human cellular immune system
|
WO2024073679A1
(en)
|
2022-09-29 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|